Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: HerbertOtto who wrote (15222)	2/17/1998 8:48:00 PM
From: Hippieslayer	Read Replies (1) \| Respond to of 32384

AGPH is a special case because their lead drug was/is targeted at a very PC disease-AIDS. Prices that are paid for these types of drugs are inflated due to the very nature of the hype associated with the disease(and the costs associated with making them). That is why I believe LGND targeted Panretin for KS. The FDA has been more lenient with companies that have drugs for AIDS (even though it afflicts a smaller amount of people compared to other devastating diseases). Beside, AGPH became a darling of Wall ST. Any company that becomes the darling of Wall st will be pushed up to prices it should never be at.